NASDAQ:GELS Gelteq (GELS) Stock Price, News & Analysis $1.10 +0.12 (+11.62%) As of 03:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Gelteq Stock (NASDAQ:GELS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gelteq alerts:Sign Up Key Stats Today's Range$1.16▼$1.9650-Day Range$0.39▼$1.5352-Week Range$0.39▼$2.12Volume58.61 million shsAverage Volume2.51 million shsMarket Capitalization$11.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK. Read More Gelteq Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreGELS MarketRank™: Gelteq scored higher than 18% of companies evaluated by MarketBeat, and ranked 763rd out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGelteq has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGelteq has only been the subject of 1 research reports in the past 90 days.Read more about Gelteq's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioGelteq has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.72% of the float of Gelteq has been sold short.Short Interest Ratio / Days to CoverGelteq has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gelteq has recently decreased by 36.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGelteq does not currently pay a dividend.Dividend GrowthGelteq does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.30 News SentimentGelteq has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Gelteq this week, compared to 2 articles on an average week.Search Interest2 people have searched for GELS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gelteq insiders have not sold or bought any company stock.Percentage Held by InstitutionsGelteq has minimal institutional ownership at this time.Read more about Gelteq's insider trading history. Receive GELS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gelteq and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GELS Stock News HeadlinesGelteq Limited (NASDAQ:GELS) Sees Significant Decline in Short InterestJune 15 at 2:14 AM | americanbankingnews.comGelteq Limited: Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq Technology for Animal Health ApplicationsJune 13 at 10:14 AM | finanznachrichten.deGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 15 at 1:00 AM | Behind the Markets (Ad)What's going on with Gelteq stock Friday?June 12 at 11:47 PM | msn.comGelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health ApplicationsJune 12 at 12:30 PM | globenewswire.comGelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial ExpansionJune 4, 2026 | globenewswire.comGelteq Calls June 19 Special Meeting to Approve Potentially Dilutive Convertible Note Share IssuanceJune 2, 2026 | tipranks.comGelteq Limited: Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory PathwayMay 20, 2026 | finanznachrichten.deSee More Headlines GELS Stock Analysis - Frequently Asked Questions How have GELS shares performed this year? Gelteq's stock was trading at $0.80 on January 1st, 2026. Since then, GELS shares have increased by 83.0% and is now trading at $1.4640. When did Gelteq IPO? Gelteq (GELS) raised $5 million in an IPO on Tuesday, October 29th 2024. The company issued 1,300,000 shares at $4.00 per share. The Benchmark Company acted as the underwriter for the IPO. How do I buy shares of Gelteq? Shares of GELS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/15/2026Planet MicroCap Las Vegas 20266/17/2026Fiscal Year End6/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 As of 4 days ago, GELS's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GELS Previous SymbolNASDAQ:GELS CIK1920092 Webwww.gelteq.com Phone61-3-9087-3990FaxN/AEmployeesN/AYear Founded2018Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110 thousand Price / Sales114.40 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book1.09Miscellaneous Outstanding Shares10,710,000Free FloatN/AMarket Cap$12.58 million OptionableN/A Beta-0.19 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free Report This page (NASDAQ:GELS) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
